Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

By S. Nissen, E. Tuzcu, Paul-Henry Schoenhagen, T. Crowe, W. Sasiela, J. Tsai, J. Orazem, R. Magorien, C. O'shaughnessy, P. Ganz. 2005

745 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Biomarkers in acute cardiac disease: the present and the future. (2006, result): “Recent data from the PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) trial (68), which are consistent with those from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid-lowering Therapy) trial (69, 70 ), suggest that the titration of statin therapy predicated on ”
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006, background): “Inflammatory markers, such as C-reactive protein and other indicators of inflammation and destabilization (67), have entered into risk formulations, offering potentially useful additions to conventional risk markers (68,69).”